ASBM Presents Poster at DIA Annual Meeting

Dr. Gewanter present a poster based on findings from ASBM's recent survey of Australian prescribers of biologics.
Dr. Gewanter presents a poster based on findings from ASBM’s recent survey of Australian prescribers of biologics.

On June 20th, ASBM Chairman Harry L. Gewanter, MD presented a poster based on ASBM’s survey of Australian biologic prescribers, at the DIA 2017 Annual Meeting in Chicago, IL. ASBM exhibited at DIA from June 19th-21st.

Dr. Gewanter answers questions from conference attendees as well as distributing literature and promotional syringe pens.
Dr. Gewanter answers questions from conference attendees at the ASBM booth, as well as distributing literature and promotional syringe pens.

The survey included 76% of prescribers believed the Therapeutic Goods Administration (TGA) should assign distinct names to all biologics, including biosimilars.

Also, 90% considered it “very important” or “critical” that the prescribing physician, with their patient, have the authority to choose the most suitable biologic for treatment. Eighty-nine percent considered it “very important” or “critical” to be notified in the event a biosimilar is substituted at the pharmacy.

View the full poster here.